Findings GLP-1 receptor agonists and dual incretin agonists exert their therapeutic effects through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of glucagon release, appetite reduction, and slowing of gastric emptying
Approval status is night and day: tirzepatide is FDA-approved (Mounjaro in 2022, Zepbound in 2023), while retatrutide is still working through Phase 3
Adequate sleep, stress management, proper hydration (especially in the desert heat), and timing your meals to minimize nausea while maximizing protein intake
Treatment courses may be longer for lesions on other sites
Final Thoughts Melanotan 1 has been well known for its natural tanning properties, especially in professional bodybuilding circles, but new studies prove it has more to offer